Kornimate/medical-research-clean huggingface dataset:
amr maneuver for prevention of postpartum hemorrhage

Conditions: Post Partum Hemorrhage

Summary: the patients were divided randomly in to 2 groups: * control group: 153 patients received oxytocin 10 iu i.v shot administered at the time of delivery of the anterior shoulder of the baby according to the who recommendation for both groups in prevention of postpartum haemorrhage,followed by active management of the third stage of labor by administration of oxytocin 5 iu units im (who gdg recommendations,2012) and waiting for signs of placental separation then controlled cord traction (cct)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(brandt andrews maneuver) * study group:156 patients received oxytocin 10 iu i.v shot at the time of delivery of the of the anterior shoulder of the baby according to the who recommendation .then oxytocin is stopped and cervical traction (amr maneuver )is applied.

the patients were divided randomly in to 2 groups: * control group: 153 patients received oxytocin 10 iu i.v shot administered at the time of delivery of the anterior shoulder of the baby according to the who recommendation for both groups in prevention of postpartum haemorrhage,followed by active management of the third stage of labor by administration of oxytocin 5 iu units im (who gdg recommendations,2012) and waiting for signs of placental separation then controlled cord traction (cct)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(brandt andrews maneuver) * study group:156 patients received oxytocin 10 iu i.v shot at the time of delivery of the of the anterior shoulder of the baby according to the who recommendation .then oxytocin is stopped and cervical traction (amr maneuver )is applied. in the maneuver,sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds. the traction should be adequate to allow the cervix to reach the vaginal introitus. meanwhile (cct ) is avoided and watchful waiting for signs of placental separartion till 90 seconds end. massage is not employed but the fundus is frequently palpaple to insure it doesnot become atonic and filled with blood from placenta separation. in cases whom placental separation did not occur within the 90 seconds, we removed the ovum forceps and waited for 30 min for the placental separation .

Eligibility criteria:
inclusion criteria: * women who candidate for vaginal delivery at casualty department singleton fetus full term pregnancy ( gestational age of more than 37 weeks). exclusion criteria: * fetal macrosomia, any case with bleeding tendency e.g: haemorrhagic diseases cases with risk of postpartum haemorrhage as: peripartun hemorrhage ( placenta previa or placental abruption), anemia or hypertension.
dupixent and narrowband uvb for atopic dermatitis

Conditions: Atopic Dermatitis

Summary: 24 weeks open-label study with dupilumab and narrowband uvb phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

24 weeks open-label study with dupilumab and narrowband uvb phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Eligibility criteria:
inclusion criteria: * male or female adult ≥ 18 years of age; * diagnosis of moderate to severe atopic dermatitis as defined at baseline by: * easi score of 16 or greater, * iga score of 3 or greater * bsa of 10% or greater, exclusion criteria: * subjects with previous exposure to dupilumab. * known or suspected hypersensitivity to dupilumab or any of its excipients. * history of photosensitivity.
egcg for hepatocellular carcinoma chemoprevention

Conditions: Cirrhosis, Liver

Summary: this phase ii trial tests epigallocatechin gallate (egcg) for its efficacy and safety in preventing development of hepatocellular carcinoma (hcc) in patients with liver cirrhosis.

this study will evaluate whether egcg favorably modulate an hcc risk biomarker (plsec) with acceptable safety profile in patients with compensated cirrhosis and elevated hcc risk determined by clinical variable-based score (fib-4 index) and plsec. sixty participants will be randomized (1:1) to either the study drub or placebo arm and receive the treatment for 24 weeks. the participants will orally take egcg 600 mg capsules or placebo for the first 12 weeks. if an interim plsec analysis at the end of week 8 is not improved without any dose-limiting adverse events, the dose will be increased to 800 mg for the second 12 weeks. if the interim plsec is improved, 600 mg will be continued. after completing the 24-week treatment, change in the plsec test with the treatment is calculated by comparing pre- and post-treatment serum samples in each patient, and the changes will be compared between the treatment arms (primary endpoint). complete adverse event profiles will be recorded, and change in quality of life will be compared between the treatment arms (secondary endpoints). if optional paired liver biopsy tissues are obtained, changes in tissue-based hcc risk biomarker (pls) and immunohistochemical markers of cell proliferation, neoplasm, senescence, and fibrogenesis will be determined, changes in the fib-4 index and liver stiffness measurement will be determined, and association with incident hcc during the study period will be evaluated (exploratory endpoints).

Eligibility criteria:
inclusion criteria: * adults (≥ 18 years-old) * clinically and/or histologically diagnosed cirrhosis * no active hepatic decompensation * no prior history of hcc * adequate hematologic, hepatic, and renal function * karnofsky performance status score ≥70 * both sexes and all racial/ethnic groups will be considered * fib-4 index \> 3.25 * high-risk plsec at baseline * absence of hla-b\*35:01 exclusion criteria: * prior or ongoing use of egcg * history of adverse reaction to green tea products * severe obesity (bmi \> 40 kg/m2) * active drinking * egcg treatment \<4 weeks or \<80% of planned regimen at the end of week 4 * hcc development during the study

Keywords: hepatocellular carcinoma chemoprevention liver cancer
package of mentholated measures for the relief of thirst in the anesthesia recovery room

Conditions: Thirst; Mouth Dryness; Irritation Lips

Summary: package of mentholated measures for the relief of thirst in the anesthesia recovery room: randomized clinical trial

perioperative thirst is intense and has a high incidence. there is evidence that strategies using cold and menthol could be viable alternatives to reduce thirst and the discomforts arising from it. for that reason, this study evaluated the efficacy of a mentholated package of measures (lip moisturizer and ice popsicle) compared to a non-mentholated package of measures in alleviating thirst in the anesthesia recovery room.

Eligibility criteria:
inclusion criteria: * possess aged between eighteen and sixty-five years * to be fasting for more than four hours * verbalizing headquarters spontaneously or after questioning, with greater than or equal to three intensity in numerical verbal scale * receive opioids or anticholinergic during surgery duration of greater than one hour anesthesia * being in anesthetic recovery in anesthesia recovery room * have been approved in the evaluation headquarter insurance management protocol which was applied to both groups * accept participate and sign the consent form clarified exclusion criteria: * being allergic to menthol * have continuity of injury in the oral mucosa * having suspended the anesthetic-surgical procedure after acceptance of participation * receive high operating room directly to another healthcare sector than the anesthetic recovery room, and intensive care unit or hospital unit

Keywords: thirst ice menthol perioperative nursing. recovery room
chemoembolization with or without mixing the chemotherapy with lipiodol for unresectable hcc

Conditions: Hepatocellular Carcinoma

Summary: tace is considered the standard treatment for unresectable hcc on the basis of the fact that there are no alternative to curative procedures.but the optimal combined regimen is still unclear. one of the controversy is do the protocol should contain lipiodo and how to executer. the investigators hypothesize that tace without mixing the chemotherapy with lipiodol is not unacceptably worse than tace mixing the chemotherapy with lipiodol.


Eligibility criteria:
eligibility criteria: inclusion criteria: * adults patients with a diagnosis of hcc which is not amenable to surgical resection ,local ablative therapy and any other cured treatment. * patients must have at least one tumor lesion that can be accurately measured according to easl criteria. and the lesion has not been previously treated with tace, surgery, radiation therapy, radiofrequency ablation, percutaneous ethanol or acetic acid injection, or cryoablation. * no serious concurrent medical illness * unresectable bclc stage a-b disease * no cirrhosis or cirrhotic status of child-pugh class a * no significant renal impairment (creatinine clearance \< 30 ml/minute) or patients on dialysis * no current infections requiring antibiotic therapy * not on anticoagulation or suffering from a known bleeding disorder * no unstable coronary artery disease or recent mi * the following laboratory parameters: * platelet count ≥ 60,000/µl * hemoglobin ≥ 8.5 g/dl * total bilirubin ≤ 1.5 mg/dl serum albumin ≥ 35 g/l * asl and ast ≤ 5 x upper limit of normal * serum creatinine ≤ 1.5 x upper limit of normal * inr ≤ 1.5 or pt/aptt within normal limits * absolute neutrophil count (anc) \>1,500/mm3 * ability to understand the protocol and to agree to and sign a written informed consent document exclusion criteria: * known history of hiv * history of organ allograft * pregnant or breast-feeding patients * known or suspected allergy to the investigational agents or any agent given in association with this trial. * cardiac ventricular arrhythmias requiring anti-arrhythmic therapy * evidence of bleeding diathesis. * patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry. * any other hemorrhage/bleeding event \> ctcae grade 3 within 4 weeks of first dose of study drug * serious non-healing wound, ulcer, or bone fracture * known central nervous system tumors including metastatic brain disease * severe arterioportal shunts or arteriavein shunts

Keywords: carcinoma,hepatocellular liver neoplasms therapeutic chemoembolization, tace pharmacokinetics iodized oil/administration & dosage polyvinyl alcohol humans
improving services and outcomes for children with autism spectrum disorder (asd)

Conditions: Autism Spectrum Disorders

Summary: based on the need to characterize and improve early intervention services for minority and under-resourced children with asd, this study translates a manualized and proven training model to examine its impact on the use of evidence-based practices (ebp) by early intervention providers, and to examine its relationship to child and family outcomes. by highlighting the impact of ebp-focused training on participating providers, children, and families, findings of the proposed study have the potential to effect significant change in the organization and delivery of early intervention services for minority and under-resourced children with asd.


Eligibility criteria:
inclusion criteria for providers: * providers must be employed by an infants and toddlers program; and * serve at least one eligible child with asd inclusion criteria for families/children: * children must be between 12 months, 0 days and 35 months, 30 days of age at entry into the study; * children must meet criteria on the autism diagnostic observation schedule (ados) for asd or autism; and * caregiver and child must be available for all assessments exclusion criteria for families/children: * children will be excluded if they are in foster care or wards of the state * caregiver must be fluent in speaking and understanding the english language

Keywords: autism early intervention minority
palliation of gastric outflow obstruction in case of concomitant biliary obstruction.

Conditions: Malignant Biliary Obstruction

Summary: eus-guided drainages has been largely widespread during the last 10 years, even thanks to the advent of dedicated devices, such as lumen apposing metal stents (lamss). above all, eus-guided choledochoduodenostomy (eus-cd) is to date considered a valuable option of treatment in case of distal malignant biliary obstruction in case of failure of endoscopic retrograde cholangiopancreatography (ercp) due to the presence of a gastric or duodenal obstruction, unreachable papilla in case of altered anatomy, infiltrated papilla or failure of deep cannulation of the common bile duct. this modality of drainage demonstrated satisfying results, with high rate both of technical and clinical success with acceptable rate of adverse events. when the distal malignant biliary obstruction is associated to signs and symptoms of gastric outflow obstruction (goo) due to the presence of a gastric or duodenal stenosis, a concomitant or subsequent palliation of the stenosis may be required. recently, eus-guided gastroenterostomy (eus-gea) has been introduced for the palliation of goo, showing good results although technically challenging. to date, endoscopic treatment in case of goo, enteral stenting and eus-gea are possible alternatives. however, available data demonstrated that eus-gea seems to be superior to enteral stenting in terms of rate of reinterventions during long-term follow-up, especially when life expectancy is superior to 6 months. however, data are lacking regarding which is the best strategy when goo is associated to distal malignant biliary obstruction, especially when eus-cd is performed. this is an hot topic, as it has been supposed that eus-cd has higher rate of adverse events, especially food impaction, when a duodenal stenosis is present. the aim of our study, therefore, is to perform a retrospective multicenter study collecting all consecutive patients affect by distal malignant biliary obstruction drained using eus-cd, with associated goo treated with concomitant or subsequent duodenal stenting or eus-gea, in order to evaluate clinical efficacy, long term outcomes and severity of adverse events.


Eligibility criteria:
inclusion criteria: - patients undergoing affected by distal malignant biliari obstruction and gastric outflow obstruction undergone eus-cd and eus-gea or enteral stenting drainage between january 2016 to september 2021 exclusion criteria: * age under 18 * enteral stenting or eus-gea performed before eus-cd * provide an estimate of number of records you plan to review and time period that it will be covered.january 2016 to september 2021 * if the number of records you plan to exceeds 500, please provide the following: n/a - provide an estimate of how long it will take you to complete the study, including the time for data analysis. 3 month for data collection and 3 weeks for data analysis
clinical study to investigate the efficacy and safety of two dose levels of nt 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions

Conditions: Chronic Troublesome Sialorrhea; Parkinson's Disease; Post-stroke; Traumatic Brain Injury

Summary: the objective of this study is to investigate the efficacy and safety of two different dose levels of nt 201 (75 u or 100 u per cycle), compared with placebo, in reducing the salivary flow rate, and the severity and frequency of chronic troublesome sialorrhea that occurs as a result of various neurological conditions in adult subjects.


Eligibility criteria:
inclusion criteria: * documented diagnosis of the basic neurological condition associated with sialorrhea (as above, (i), (ii) or (iii); with onset at least 6 months before screening). * chronic troublesome sialorrhea related to parkinsonism or stroke or traumatic brain injury (for at least 3 months) at screening, defined as the presence of all of the following, at screening and at baseline and for at least the 3 months before screening (where retrospective response to questionnaires is impossible, a statement of equivalent severity will suffice): 1. a drooling severity and frequency scale \[dsfs\] sum score of at least 6 points and 2. a score of at least 2 points for each item of the dsfs and 3. a score of at least 3 points on the modified radboud oral motor inventory for parkinson's disease \[mromp\], section 'iii drooling', item a). * a score of at most 2 points on the mromp section 'ii swallowing symptoms' item a) and a score of at most 3 points on item c), at screening and at baseline. exclusion criteria: * non-neurological secondary causes of sialorrhea. * unstable concomitant medication influencing sialorrhea (such as anticholinergics for the treatment of parkinsonism; dosages of these medications must have been stable for at least 4 weeks before study entry, i.e. screening, and must be planned to remain stable during the course of the study. * recent (i.e., four weeks) drug treatment for sialorrhea. * history of recurrent aspiration pneumonia. * extremely poor dental/oral condition as assessed by a qualified dentist. * recent (i.e., one year for sialorrhea, 14 weeks for other indications) treatment with - or known hypersensitivity to - botulinum toxin, or known hypersensitivity to any ingredient of the study preparation. * recent (i.e., four weeks) changes in anti-parkinsonian medication. * previous or planned surgery or irradiation to control sialorrhea.
daily life activities in patients treated with continuous-flow left ventricular assist devices

Conditions: Left Ventricular Failure, Unspecified

Summary: investigation of oxygen uptake during daily life activities in hf patients with and without lvads.

in patients with terminal hf the gold standard for treatment is heart transplantation, though the worldwide shortage of donor organs has led to increased use of implantable mechanical circulatory support devices. the treatment with implantable pumps in the form of a continuous flow left ventricular assist device (cf-lvad, or simply lvad) is extremely effective for a selected patient groups leading to significant improvement in survival and quality of life. the device is a battery-powered flow pump that carries the blood from the left ventricle to the main artery, via a cannula, and thus relieves the failing left ventricle with up to 10 liters of blood per minute. an lvad can be used both as lifelong support therapy (destination therapy, dt) or until transplantation can take place (bridge therapy). as patients today live for more than 10 years with the device as dt, the focus has shifted from mere survival to quality of life and physical ability. in recent years, our research group showed that the pump speed and the patient's baseline heart rhythm (sinus rhythm vs atrial fibrillation) and reduced ability to regulate the intrinsic rhythm after implantation (chronotropic incompetence) are significant contributors to the reduced exercise capacity seen in this patient group. until now, studies have elucidated the work capacity of this patient group using a 6-minute walk test or bicycle test - none of these reflect how well the patient actually functions in his everyday life. in this study, we will describe oxygen uptake related to specific daily activities (adl-vo2) and compare these with the well-known maximum work capacity (percentage of expected oxygen uptake / pvo2) in this patient group.

Eligibility criteria:
lvads: inclusion criteria: * implanted durable left ventricular assist device * age\>18yrs * signed informed consent exclusion criteria: * no consent * not able to complete vo2 test (physicians decision)

Keywords: left ventricular assist device oxygen uptake daily life activity quality of life
ansistim study for active labor pain

Conditions: Labor Pain; Obstetric Pain

Summary: the specific aim of the study is to do comparison between ansistim and placebo for pain relief in labor. during the treatment, pain relief will be assesed with ansistim in active labor through continues checking of vas score. ansistim has been tried in post operative patients with good pain relief .

pain during labor is caused by contractions of the muscles of the uterus and by pressure on the cervix. this pain can be felt as strong cramping in the abdomen, groin, and back, as well as an achy feeling. some women experience pain in their sides or thighs as well. most women have an epidural or spinal during labour or after the birth.

Eligibility criteria:
inclusion criteria: * pregnant women on an active labor exclusion criteria: * cardiac pacemaker or any other implants * psoriasis * diminish mental capacity
effect of nap on daytime functioning in primary school students

Conditions: Sleep Deprivation

Summary: previous studies showed that insufficient sleep has a negative impact on children's physical and psychological health. napping was found to decrease sleepiness and improve daytime functioning in adults and adolescents. the effects of napping on children, however, is unknown. the current study aims to test the effects of short daytime classroom naps on daytime functioning and behaviour in elementary school children.

this study is an interventional study testing the effects of short daytime nap on children's cognitive functioning and daytime behaviour. primary school children will be randomised to either experimental (nap) or control group (no nap) by class. measurements include parent-report questionnaires, children's self-report questionnaires, and cognitive tasks.

Eligibility criteria:
inclusion criteria: * children from grade 1, 2, 3, 5, and 6 exclusion criteria: * children ages 4 or younger, ages 15 or older

Keywords: primary school children nap sleep deprivation
perioperative inflammation and breast cancer outcome

Conditions: Breast Neoplasms

Summary: it is increasingly recognized the nsaids (nonsteroidal antiinflammatory drug) might prevent the several cancers. in breast cancer, the role of nsaids (nonsteroidal antiinflammatory drug) has been suggested.however, there was no consistent results. surgery is main cause of inflammation for cancer patients. therefore, we want to know the association between prevention of perioperative inflammation with nsaids and breast cancer outcomes.


Eligibility criteria:
inclusion criteria: * breast cancer patients who took the surgery exclusion criteria: * underlying medical disease (major heart disease, lung disease, coagulopathy) * major psychologic disease (major depression, schizophrenia, manic disorder) * pregnancy * rheumatic disease patients

Keywords: anti-inflammatory agents, non-steroidal inflammation perioperative period